Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

February 24, 2023

https://www.globenewswire.com/news-release/2023/02/24/2615117/0/en/Pharvaris-to-Highlight-Positive-Phase-2-Data-from-RAPIDe-1-Study-of-PHVS416-for-the-On-Demand-Treatment-of-HAE-Attacks-at-AAAAI-Annual-Meeting.html

ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks will be presented at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, being held from February 24-27, 2023, in San Antonio, TX.

Read more at globenewswire.com

Related news for (PHVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.